The use of mTOR inhibitors as an alternative therapeutic strategy has demonstrated some success in KIT-activated melanoma, thereby suggesting that mTOR inhibitors as a monotherapy or in combination with first-line kinase inhibitors may be effective in targeting kinase-inhibitor-resistant tumors [77]. This evidence concerns the gene MTOR and melanoma.